Certain features of will be down for maintenance the evening of Friday August 18th starting at 8:00 pm CDT until Saturday August 19th at 12:01 pm CDT.   Please note that you still have telephone and email access to our local offices. We apologize for any inconvenience.

Comparison of SupelMIP™ SPE – Beta-agonists and Mixed-mode SPE for the Extraction of beta-agonists from Urine Samples

By: Olaf Heemken, Anna-Karin Whilborg, Reporter US Volume 26.4

Olaf Heemken1 and Anna-Karin Whilborg2
1 LAVES, Veterinary Institute, Oldenburg, Germany
2 MIP Technologies AB, Lund, Sweden


Beta-2-adrenergic receptor agonists (Beta-agonists) have been clinically used in the treatment of cardiovascular and breathing disorders in veterinary and human medicine. However, beta-agonists are also used as an illegal muscle growth promoter due to its anabolic effects both in humans and in animals. Although the US Food and Drug Administration, US Department of Agricultural and European Union have banned the use of beta-agonists for humans and livestock, illegal use of this class of drugs still frequently occurs. For example, the beta-agonist clenbuterol is widely used among body builders and athletes due to its anabolic effects. In addition, beta-agonists are readily used by farmers to give animals a competitive advantage. Due to the potential health risks and competitive advantage associated with beta-agonist used in livestock and human performance enhancement, residue screening programs are conducted worldwide to monitor the drug. It is therefore critical to develop a highly selective and sensitive analytical assay to monitor beta-agonist residues in difficult biological matrices such as urine, retina, tissues, etc. Table 1 offers an overview of the minimum required performance levels (MRPLs) required of an assay across common sample matrices.

Table 1. MRPLs of Beta-Agonist Assays in Different Matrices

In this article, a summary of the work performed at the Veterinary Institute in Oldenburg, Germany is presented. In order to enhance the methods for analyzing beta-agonists, the use of a molecularly imprinted polymer SPE phase (developed specifically for beta-agonist extraction) was explored. More specifically, SupelMIP – Beta-agonist SPE was evaluated for urine samples and compared against a conventional mixed-mode SPE procedure.

back to top


In this work, beta-agonist spiked calf urine samples were extracted and compared using both SupelMIP SPE – Beta-agonist, 25 mg/10 mL LRC and Clean Screen DAU SPE, 500 mg/6 mL (United Chemical Technologies, PA, USA). The SupelMIP extraction and analysis method is detailed in Table 2.

Table 2. SupelMIP SPE – Beta-agonist Extraction Method (Prod. No.G0876) (Cat. No.53210-U)

back to top


In order to evaluate the performance of the SupelMIP SPE, beta-agonist spiked urine was extracted and compared against Clean Screen DAU SPE (mixed-mode). Figure 1 depicts ion-chromatograms of salmeterol extracted with both SupelMIP SPE and Clean Screen DAU. From this figure, background for salmeterol using SupelMIP is significantly lower than the mixed-mode approach. In addition, response height was greater using the SupelMIP method.

Figure 1. Ion-chromatogram of Salmeterol (0.2 μg/L spike, MRM 240/148) extracted via SupelMIP SPE and Clean Screen DAU SPE

In Figure 2, ion-chromatograms of clenbuterol and clenproperol are illustrated. Both compounds were extracted from urine using SupelMIP SPE and Clean Screen DAU. Response was increased by a factor of 10 for both beta-agonists using the SupelMIP SPE approach relative to mixed-mode.

Figure 2. Ion-Chromatograms of Clenbuterol (0.05 μg/L spike, MRM 277/203) and Clenproperol (0.4 μg/L spike, MRM 263/245) extracted via SupelMIP SPE and Clean Screen DAU SPE

In Table 3, the signal-to-noise (S/N) ratio for a broad range of beta-agonists (target ion and qualifier) are presented. For each of the beta-agonists, the SupelMIP approach provided a cleaner and more selective extraction. As a result S/N was significantly higher (often by orders of magnitude)

Table 3. Signal-to-Noise Ratio of Beta-agonists

back to top


In this work it was concluded that the SupelMIP SPE – Beta-agonists is a highly selective phase for Beta-agonists. This high selectivity for the class of compounds allows for very clean extracts with low levels of interfering contaminants. Comparing the performance with general mixedmode phases, a clear enhancement in the signal to noise ratio is obtained using the SupelMIP phase, allowing for increased analytical sensitivity and lower detection levels.

The method as described fulfills all criteria of the EU Commission Decision 2002/657/EC for confirmatory analysis of substances listed in group A of Annex I of Council Directive 96/23/EC and has been adopted for routine analysis by the Veterinary Institute Oldenburg.

back to top


Related Links